Absentia Labs is a biotechnology company headquartered in Boston, Massachusetts, that develops artificial intelligence systems to accelerate drug development. Founded by MIT-trained scientists, the company builds foundation models trained on biological, chemical, and clinical data. These models are designed to predict drug behavior, safety, and efficacy, supporting decision-making across the pharmaceutical pipeline.
The company's technical work spans several domains, including AI foundation models, drug discovery, and in-silico modeling. Its approach focuses on creating generalizable models from large-scale biological and clinical datasets rather than narrow, single-task tools.
Absentia Labs' product portfolio includes the Digital Liver Model, an AI system for predicting Drug-Induced Liver Injury (DILI). This tool is notable for being the first AI drug development tool accepted into the FDA's Drug Development Tool Qualification Program, a significant regulatory milestone in the use of AI for pharmaceutical development.
